Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the ...

When pediatric health experts name the most worrisome medical conditions plaguing young people today, obesity often tops the list. According to global statistics from the World Health Organization, ...

A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

Individuals with obesity developed related comorbidities earlier and more frequently than those with normal BMI, with musculoskeletal pain being the most common, a large cohort study finds.

Discover expert tips from an obesity medicine doctor on effective and sustainable ways to approach weight loss for type 2 ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...